Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.38 |
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL4468654 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL6428278 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL1255583 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL8043620 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL5973421 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL8868 | 0.84 | — | — | |
| Isoleucine SCHEMBL8045737 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL8186739 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL1255582 | 0.84 | SLC7A5 (0.55) | DPP4DPP8DPP9SLC7A5DPP7 | |
| Isoleucine SCHEMBL20340795 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2009-07-02 | — | — | US | disclosed |
| CN-100382795-C | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2008-04-23 | — | — | CN | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060188920-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | BALZARINI JAN MARIA R | 2006-08-24 | — | — | US | disclosed |
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | BALZARINI JAN MARIA R | 2006-08-17 | — | — | US | disclosed |
| CN-1777414-A | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| EP-1603546-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | Tripep AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | TRIPEP AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | GALE, ENGASE, GLMN | DPP4 625/4885DPP8 403/4885DPP9 664/4885 |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | GALE, ENGASE, GLMN | DPP4 449/4885DPP8 202/4885DPP9 679/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | DPP4 725/4885DPP8 533/4885DPP9 819/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | DPP4 380/4885DPP8 213/4885DPP9 401/4885 |
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | OGA, ENGASE, GALE | DPP4 320/4885DPP8 275/4885DPP9 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.